Complexities of diagnosis and treatment of allergic respiratory disease in the elderly

Drugs and Aging

Volumn 26, Issue 1, 2009, Pages 1-22

  Busse, Paula J ^a   Kilaru, Kiran ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic rhinitis, general; Antihistamines, therapeutic use; Asthma, general; Beta 2 adrenergic receptor agonists, therapeutic use; Corticosteroids, therapeutic use; Decongestants, therapeutic use; Elderly; Leukotriene modulators, therapeutic use

Indexed keywords

ACRIVASTINE; ALLERGEN; ANTIHYPERTENSIVE AGENT; AZELASTINE; CETIRIZINE; CHLORPHENIRAMINE; CLONIDINE; CORTICOSTEROID; CYPROHEPTADINE; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYZINE; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; KETOTIFEN; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MONTELUKAST; PRAZOSIN; PSEUDOEPHEDRINE; UNINDEXED DRUG;

AGED; AGING; ALERTNESS; ALLERGIC RHINITIS; ANXIETY; ASTHMA; AVOIDANCE BEHAVIOR; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; CONFUSION; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG INDICATION; EVENING DOSAGE; GLAUCOMA; HEART RATE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSOMNIA; IRRITABILITY; NOSE CONGESTION; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PREVALENCE; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SEDATION; SIDE EFFECT; XEROSTOMIA;

AGED; ASTHMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 58149114639     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200926010-00001     Document Type: Review

References (183)

1. Howarth PH. Allergic and nonallergic rhinitis. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Middleton's allergy principles & practice. Philadelphia (PA): Mosby, 2003: 1391-410
2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368 (9537): 733-43
3. Warner JO, Kaliner MA, Crisci CD, et al. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol 2006; 139 (2): 166-74
4. Weinmayr G, Forastiere F, Weiland SK, et al. International variation in prevalence of rhinitis and its relationship with sensitization to perennial and seasonal allergies. Eur Respir J 2008; 32 (5): 1250-61
5. Kerkhof M, Droste JH, de Monchy JG, et al. Distribution of total serum IgE and specific IgE to common aeroallergens by sex and age, and their relationship to each other in a random sample of the Dutch general population aged 20-70 years. Dutch ECRHS Group, European Community Respiratory Health Study. Allergy 1996; 51 (11): 770-6
6. Huss K, Naumann PL, Mason PJ, et al. Asthma severity, atopic status, allergen exposure and quality of life in elderly persons. Ann Allergy Asthma Immunol 2001; 86 (5): 524-30
7. Hadley JA. Evaluation and management of allergic rhinitis. Med Clin North Am 1999; 83 (1): 13-25
8. Enright PL, Kronmal RA, Higgins MW, et al. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994; 106 (3): 827-34
9. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006; 117 (1): 158-62
10. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007; 28 (1): 3-9
11. Bernstein JM, Lee J, Conboy K, et al. Further observations on the role of IgE-mediated hypersensitivity in recurrent otitis media with effusion. Otolaryngol Head Neck Surg 1985; 93 (5): 611-5
12. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl. 86: 8-160
13. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002; 88 (4 Suppl. 1): 2-7
14. Sahin Yilmaz AA, Corey JP. Rhinitis in the elderly. Curr Allergy Asthma Rep 2006; 6: 125-31
15. Zohar Y, Talmi YP, Strauss M, et al. Ozena revisited. J Otolaryngol 1990; 19 (5): 345-9
16. Slavin RG. Allergic rhinitis: managing the adult spectrum. Allergy Asthma Proc 2006; 27 (1): 9-11
17. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl.): S147-334
18. Garay R. Mechanisms of vasomotor rhinitis. Allergy 2004; 59 Suppl. 76: 4-9; discussion 9-10
19. Patel PN, Oyefara B, Aarstad R, et al. Rhinorrhea not responding to nasal corticosteroids. Allergy Asthma Proc 2007; 28 (6): 735-8
20. King MJ, Lockey RF. Allergen prick-puncture skin testing in the elderly. Drugs Aging 2003; 20 (14): 1011-7
21. Skassa-Brociek W, Manderscheid JC, Michel FB, et al. Skin test reactivity to histamine from infancy to old age. J Allergy Clin Immunol 1987; 80 (5): 711-6
22. Gosepath J, Amedee RG, Mann WJ. Nasal provocation testing as an international standard for evaluation of allergic and nonallergic rhinitis. Laryngoscope 2005; 115 (3): 512-6
23. Platts-Mills TA, Vaughan JW, Carter MC, et al. The role of intervention in established allergy: avoidance of indoor allergens in the treatment of chronic allergic disease. J Allergy Clin Immunol 2000; 106 (5): 787-804
24. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma 2007. Bethesda (MD): National Institutes of Health; 2007 Aug. Report No.: NIH Publication 07-4051
25. Bielory L. Intranasal corticosteroids reduce ocular symptoms of allergic rhinitis as a class effect. J Allergy Clin Immunol 2007; 119 (6): 1430-7
26. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 1999; 104 (4 Pt 1): S144-9
27. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2007; 28 (2): 145-52
28. Holm AF, Fokkens WJ, Godthelp T, et al. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol Allied Sci 1998; 23 (1): 69-73
29. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118 (5): 648-54
30. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999; 83 (3): 153-79
31. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 1998; 101 (4 Pt 1): 470-4
32. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 598-604
33. Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169 (1): 83-8
34. Opatowsky I, Feldman RM, Gross R, et al. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995; 102 (2): 177-9
35. Bui CM, Chen H, Shyr Y, et al. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005; 116 (5): 1042-7
36. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2006; 96 (4): 514-25
37. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000; 105 (5): 912-6
38. Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc 2000; 21 (1): 15-20
39. Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998; 101 (3): 410-20
40. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107 (4): 751-62
41. Albanesi C, Pastore S, Fanales-Belasio E, et al. Cetirizine and hydrocortisone differentially regulate ICAM-1 expression and chemokine release in cultured human keratinocytes. Clin Exp Allergy 1998; 28 (1): 101-9
42. Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006; 118 (5): 985-98
43. Hansen J, Klimek L, Hormann K. Pharmacological management of allergic rhinitis in the elderly: safety issues with oral antihistamines. Drugs Aging 2005; 22 (4): 289-96
44. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89 (5): 485-91
45. Horak F, Stubner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109 (6): 956-61
46. Ciprandi G, Cosentino C, Milanese M, et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56 (11): 1068-70
47. Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 2002; 22 (11): 1458-67
48. McCue JD. Safety of antihistamines in the treatment of allergic rhinitis in elderly patients. Arch Fam Med 1996; 5 (8): 464-8
49. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341 (7): 468-75
50. Eidelman FJ. Efficacy of allergy immunotherapy in the elderly [abstract]. J Allergy Clin Immunol 2000; 105: S313
51. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol 2004; 135 (4): 332-5
52. Nelson HS. Immunotherapy for inhalant allergens. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Middleton's allergy principles & practice. Philadelphia (PA): Mosby, 2003: 1455-73
53. Tinkelman DG, Cole 3rd WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995; 95 (1 Pt 1): 8-14
54. Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986; 77 (6): 865-70
55. Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113 (6): 1129-36
56. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105 (5): 917-22
57. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88 (6): 592-600
58. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007; 67 (6): 887-901
59. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91 (2): 160-7
60. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286 (23): 2956-67
61. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59 (7): 709-17
62. Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000; 55 (3): 194-7
63. Busse WW, Lemanske Jr RF. Asthma. N Engl J Med 2001; 344 (5): 350-62
64. Burrows B, Barbee RA, Cline MG, et al. Characteristics of asthma among elderly adults in a sample of the general population. Chest 1991; 100 (4): 935-42
65. Martinez FD, Holt PG. Role of microbial burden in aetiology of allergy and asthma. Lancet 1999; 354 Suppl. 2: SII12-5
66. Enright PL, McClelland RL, Newman AB, et al. Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest 1999; 116 (3): 603-13
67. Braman SS. Asthma in the elderly. Clin Geriatr Med 2003; 19 (1): 57-75
68. Kim YK, Kim SH, Tak YJ, et al. High prevalence of current asthma and active smoking effect among the elderly. Clin Exp Allergy 2002; 32 (12): 1706-12
69. Malik A, Saltoun CA, Yarnold PR, et al. Prevalence of obstructive airways disease in the disadvantaged elderly of Chicago. Allergy Asthma Proc 2004; 25 (3): 169-73
70. Parameswaran K, Hildreth AJ, Chadha D, et al. Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. Respir Med 1998; 92 (3): 573-7
71. Banerjee DK, Lee GS, Malik SK, et al. Underdiagnosis of asthma in the elderly. Br J Dis Chest 1987; 81 (1): 23-9
72. Robin ED. Death from bronchial asthma. Chest 1988; 93 (3): 614-8
73. Moorman JE, Rudd RA, Johnson CA, et al. and Centers for Disease Control and Prevention (CDC). National surveillance for asthma: United States, 1980-2004. MMWR Surveill Summ 2007; 56 (8): 1-54
74. Diette GB, Krishan J, Dominici F, et al. Why do older adults have higher rates of hospitalization for asthma than younger adults? In: American Thoracic Society International Conference; 2000, Toronto
75. Sly RM. Changing asthma mortality. Ann Allergy 1994; 73 (3): 259-68
76. Diette GB, Krishnan JA, Dominici F, et al. Asthma in older patients: factors associated with hospitalization. Arch Intern Med 2002; 162 (10): 1123-32
77. Hartert TV, Speroff T, Togias A, et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002; 89 (5): 467-73
78. Hardie JA, Vollmer WM, Buist AS, et al. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med 2005; 99 (2): 186-95
79. Peat JK, Britton WJ, Salome CM, et al. Bronchial hyperresponsiveness in two populations of Australian schoolchildren. III: effect of exposure to environmental allergens. Clin Allergy 1987; 17 (4): 291-300
80. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320 (5): 271-7
81. Ariano R, Panzani RC, Augeri G. Late onset asthma clinical and immunological data: importance of allergy. J Investig Allergol Clin Immunol 1998; 8 (1): 35-41
82. Litonjua AA, Sparrow D, Weiss ST, et al. Sensitization to cat allergen is associated with asthma in older men and predicts new-onset airway hyperresponsiveness. The Normative Aging Study. Am J Respir Crit Care Med 1997; 156 (1): 23-7
83. King MJ, Bukantz SC, Phillips S, et al. Serum total IgE and specific IgE to Dermatophagoides pteronyssinus, but not eosinophil cationic protein, are more likely to be elevated in elderly asthmatic patients. Allergy Asthma Proc 2004; 25 (5): 321-5
84. Rogers L, Cassino C, Berger KI, et al. Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers. Chest 2002; 122 (5): 1580-6
85. Hizawa N, Yamaguchi E, Konno S, et al. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med 2002; 166 (5): 686-90
86. Hizawa N, Yamaguchi E, Jinushi E, et al. A common FCER1B gene promoter polymorphism influences total serum IgE levels in a Japanese population. Am J Respir Crit Care Med 2000; 161 (3 Pt 1): 906-9
87. Ruse CE, Hill MC, Burton PR, et al. Associations between polymorphisms of the high-affinity immunoglobulin E receptor and late-onset airflow obstruction in older populations. J Am Geriatr Soc 2003; 51 (9): 1265-9
88. Bodner CH, Ross S, Little J, et al. Risk factors for adult onset wheeze: a case control study. Am J Respir Crit Care Med 1998; 157 (1): 35-42
89. Bauer BA, Reed CE, Yunginger JW, et al. Incidence and outcomes of asthma in the elderly: a population-based study in Rochester, Minnesota. Chest 1997; 111 (2): 303-10
90. Mitsunobu F, Mifune T, Hosaki Y, et al. IgE-mediated and age-related bronchial hyperresponsiveness in patients with asthma: relationship to family history of the disease. Age Ageing 2000; 29 (3): 215-20
91. Gern JE. Viral respiratory infection and the link to asthma. Pediatr Infect Dis J 2004; 23 (1 Suppl.): S78-86
92. ten Brinke A, van Dissel JT, Sterk PJ, et al. Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001; 107 (3): 449-54
93. O'Connor GT, Sparrow D, Segal MR, et al. Smoking, atopy, and methacholine airway responsiveness among middle-aged and elderly men. The Normative Aging Study. Am Rev Respir Dis 1989; 140 (6): 1520-6
94. Mitsunobu F, Ashida K, Hosaki Y, et al. Influence of long-term cigarette smoking on immunoglobulin E-mediated allergy, pulmonary function, and high-resolution computed tomography lung densitometry in elderly patients with asthma. Clin Exp Allergy 2004; 34 (1): 59-64
95. Cuttitta G, Cibella F, Bellia V, et al. Changes in FVC during methacholine-induced bronchoconstriction in elderly patients with asthma: bronchial hyperresponsiveness and aging. Chest 2001; 119 (6): 1685-90
96. Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149 (2 Pt 1): 430-8
97. Braman SS, Davis SM. Wheezing in the elderly: asthma and other causes. Clin Geriatr Med 1986; 2 (2): 269-83
98. Connolly MJ, Crowley JJ, Charan NB, et al. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 1992; 47 (6): 410-3
99. Brusasco V, Crimi E, Pellegrino R. Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax 1998; 53 (11): 992-8
100. Davis PB, Byard PJ. Relationships among airway reactivity, pupillary alpha-adrenergic and cholinergic responsiveness, and age. J Appl Physiol 1988; 65 (1): 200-4
101. Pfeifer MA, Weinberg CR, Cook D, et al. Differential changes of autonomic nervous system function with age in man. Am J Med 1983; 75 (2): 249-58
102. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999; 103 (4): 539-47
103. Enright PL, Kronmal RA, Higgins M, et al. Spirometry reference values for women and men 65 to 85 years of age. Cardiovascular Health Study. Am Rev Respir Dis 1993; 147 (1): 125-33
104. Pezzoli L, Giardini G, Consonni S, et al. Quality of spirometric performance in older people. Age Ageing 2003; 32 (1): 43-6
105. Bellia V, Pistelli R, Catalano F, et al. Quality control of spirometry in the elderly. The SA.R.A. study. SAlute Respiration nell'Anziano = Respiratory Health in the Elderly. Am J Respir Crit Care Med 2000; 161 (4 Pt 1): 1094-100
106. Lehmann S, Vollset SE, Nygaard HA, et al. Factors determining performance of bronchodilator reversibility tests in middle-aged and elderly. Respir Med 2004; 98 (11): 1071-9
107. De Filippi F, Tana F, Vanzati S, et al. Study of respiratory function in the elderly with different nutritional and cognitive status and functional ability assessed by plethysmographic and spirometric parameters. Arch Gerontol Geriatr 2003; 37 (1): 33-43
108. Black LD, Dellaca R, Jung K, et al. Tracking variations in airway caliber by using total respiratory vs. airway resistance in healthy and asthmatic subjects. J Appl Physiol 2003; 95 (2): 511-8
109. Martin RJ, Wanger JS, Irvin CG, et al. Methacholine challenge testing: safety of low starting FEV1. Asthma Clinical Research Network (ACRN). Chest 1997; 112 (1): 53-6
110. Hopp RJ, Bewtra A, Nair NM, et al. The effect of age on methacholine response. J Allergy Clin Immunol 1985; 76 (4): 609-13
111. Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol 2008; 8 (3): 222-35
112. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31 (1): 143-78
113. NAEPP Working Group Report: Considerations for Diagnosis and Managing Asthma in the Elderly; 1996. Bethesda (MD): NIH Publication No. 96-3662, 2006 February
114. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113 (1): 59-65
115. Bijl-Hofland ID, Cloosterman SG, van Schayck CP, et al. Perception of respiratory sensation assessed by means of histamine challenge and threshold loading tests. Chest 2000; 117 (4): 954-9
116. Janson SL, Fahy JV, Covington JK, et al. Effects of individual self-management education on clinical, biological, and adherence outcomes in asthma. Am J Med 2003; 115 (8): 620-6
117. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
118. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing 2003; 32 (3): 299-302
119. Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988; 17 (4): 275-8
120. Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 1993; 104 (5): 1332-7
121. Pounsford JC. Nebulisers for the elderly. Thorax 1997; 52 Suppl. 2: S53-5
122. Marabini A, Brugnami G, Curradi F, et al. Short-term effectiveness of an asthma educational program: results of a randomized controlled trial. Respir Med 2002; 96 (12): 993-8
123. Clark NM, Gong M, Schork MA, et al. Long-term effects of asthma education for physicians on patient satisfaction and use of health services. Eur Respir J 2000; 16 (1): 15-21
124. Harrison BD. Psychosocial aspects of asthma in adults. Thorax 1998; 53 (6): 519-25
125. Gotzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008 (2): CD001187
126. Wolfenden LL, Diette GB, Skinner EA, et al. Gaps in asthma care of the oldest adults. J Am Geriatr Soc 2002; 50 (5): 877-83
127. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29 (2): 281-8
128. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 1997; 80 (9B): 15J-9J
129. Kitch BT, Levy BD, Fanta CH. Late onset asthma: epidemiology, diagnosis and treatment. Drugs Aging 2000; 17 (5): 385-97
130. Graft DF, Fowles J, McCoy CE, et al. Detection of beta-blocker use in people with asthma. Ann Allergy 1992; 69 (5): 449-53
131. Odeh M, Oliven A, Bassan H. Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991; 32 (1): 97-8
132. Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162 (1): 34-9
133. Weiss ST. Obesity: insight into the origins of asthma. Nat Immunol 2005; 6 (6): 537-9
134. Stenius-Aarniala B, Poussa T, Kvarnstrom J, et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000; 320 (7238): 827-32
135. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145 (3): 669-74
136. Vignola AM, Riccobono L, Profita M, et al. Effects of low doses of inhaled fluticasone propionate on inflammation and remodelling in persistent-mild asthma. Allergy 2005; 60 (12): 1511-7
137. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340 (25): 1948-53
138. Sin DD, Tu JV. Underuse of inhaled steroid therapy in elderly patients with asthma. Chest 2001; 199 (3): 720-5
139. Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160 (6): 2555-9
140. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338 (21): 1516-20
141. Vollmer WM, O'Hollaren M, Ettinger KM, et al. Specialty differences in the management of asthma: a cross-sectional assessment of allergists' patients and generalists' patients in a large HMO. Arch Intern Med 1997; 157 (11): 1201-8
142. Vilar ME, Reddy BM, Silverman BA, et al. Superior clinical outcomes of inner city asthma patients treated in an allergy clinic. Ann Allergy Asthma Immunol 2000; 84 (3): 299-303
143. Hartert TV, Togias A, Mellen BG, et al. Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. J Am Geriatr Soc 2000; 48 (6): 651-7
144. Bisgaard H, Nikander K, Munch E. Comparative study of budesonide as a nebulized suspension vs pressurized metered-dose inhaler in adult asthmatics. Respir Med 1998; 92 (1): 44-9
145. Marcus P, Oppenheimer EA, Katz LM, et al. Use of nebulized budesonide inhalation suspension among older adult and elderly patients: an assessment of outcomes [abstract]. Allergy Asthma Proc 2005; 26 (3): 235
146. Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001; 24 (14): 1065-80
147. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary- adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 2007; 98 (2): 118-27
148. Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs 2008; 68 (12): 1741-70
149. Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994; 105 (6): 1722-7
150. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345 (13): 941-7
151. Marystone JF, Barrett-Connor EL, Morton DJ. Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Am J Public Health 1995; 85 (12): 1693-5
152. de Vries F, van Staa TP, Bracke MS, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25 (5): 879-84
153. Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med 2003; 114 (2): 142-5
154. Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005; 94 (1): 15-21; quiz 2-3, 79
155. Campbell IA, Douglas JG, Francis RM, et al. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004; 59 (9): 761-8
156. Kasayama S, Fujita M, Goya K, et al. Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. Metabolism 2005; 54 (1): 85-90
157. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999; 83 (3): 153-79
158. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337 (1): 8-14
159. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280 (6): 539-43
160. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27 (6): 1168-74
161. Leone FT, Fish JE, Szefler SJ, et al. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest 2003; 124 (6): 2329-40
162. Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999; 106 (12): 2301-6
163. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277 (9): 722-7
164. Patten SB, Lavorato DH. Medication use and major depressive syndrome in a community population. Compr Psychiatry 2001; 42 (2): 124-31
165. Bender BG. Risk taking, depression, adherence, and symptom control in adolescents and young adults with asthma. Am J Respir Crit Care Med 2006; 173 (9): 953-7
166. Dekhuijzen PN, Koopmans PP. Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet 2002; 41 (2): 105-14
167. Lu P, Schrag ML, Slaughter DE, et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31 (11): 1352-60
168. Korenblat PE, Kemp JP, Scherger JE, et al. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol 2000; 84 (2): 217-25
169. Creticos P, Knobil K, Edwards LD, et al. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol 2002; 88 (4): 401-9
170. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167 (6): 813-8
171. Lam A, Newhouse MT. Management of asthma and chronic airflow limitation: are methylxanthines obsolete? Chest 1990; 98 (1): 44-52
172. Shannon M, Lovejoy Jr FH. The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. Arch Intern Med 1990; 150 (10): 2045-8
173. Connolly MJ, Crowley JJ, Charan NB, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 1995; 108 (2): 401-6
174. Braman SS, Hanania NA. Asthma in older adults. Clin Chest Med 2007; 28 (4): 685-702
175. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003; 2 (4): 287-97
176. Holland OB, Nixon JV, Kuhnert L. Diuretic-induced ventricular ectopic activity. Am J Med 1981; 70 (4): 762-8
177. Mansfield LE. The future of the long-acting beta-adrenergic bronchodilators in the treatment of asthma. Allergy Asthma Proc 2008; 29 (2): 103-8
178. Easton PA, Jadue C, Dhingra S, et al. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315 (12): 735-9
179. Busse WW, Massanari M, Kianifard F, et al. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007; 23 (10): 2379-86
180. Hendeles L, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother 2007; 41 (9): 1397-410
181. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008; 63 (6): 670-84
182. Plosker GL, Keam SJ. Omalizumab: a review of its use in the treatment of allergic asthma. Biodrugs 2008; 22 (3): 189-204
183. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120 (6): 1373-7